Key result
Sotalol at 10 mg/L produced anti-fibrillatory effects by prolonging action potential duration and flattening the maximal slope of restitution, reducing VT/VF inducibility from 91.1% to 25%.
Why the study?
Does d,l-sotalol alter action potential duration restitution kinetics and affect VT/VF inducibility in isolated swine right ventricles?
Does d,l-sotalol alter action potential duration restitution kinetics and affect VT/VF inducibility in isolated swine right ventricles?
Absolute Event Rate: 0.25% vs 1.8%
p-value: p=<0.01
Therapeutic doses of sotalol exert anti-fibrillatory effects by flattening APDR kinetics, while higher doses may be proarrhythmic by steepening these kinetics.
Sotalol may reduce VT/VF inducibility via APDR flattening in swine ventricles; leaves open translation to human arrhythmia management.
Background and Objectives:The action potential duration (APD) restitution kinetics has been known to play a crucial role in the initiation and maintenance of ventricular tachycardia (VT)/fibrillation (VF). We hypothesized that “the anti-arrhythmic and proarrhythmic effects of d,l-sotalol are mediated by changing the APD restitution (APDR) kinetics”. Materials and Methods:The purposes of this study were: 1) to assess the effects of d,lsotalol on the APDR kinetics, and 2) to correlate the anti-arrhythmic and proarrhythmic action using the APDR kinetics. We recorded the transmembrane potentials (TMPs), using the microelectrode technique, in seven isolated perfused swine right ventricles, at the baseline, and with 1, 5, 10 and 20 mg/L of d,l-sotalol, with a washout period of 1 hour. The ventricular effective refractory periods (VERP), APD at 90% repolarization (APD90), spontaneous defibrillation rate and VF inducibility were measured at each concentration. We plotted APDR curves of S1-S2 pacing against VF, and calculated the maximal slopes (Smax) of the APDR. Results: Sotalol (10 mg/L) prolonged the APD90 (p<0.001) by reducing the Smax of the APDR (by S1-S2 pacing, p<0.01; during VF, p<0.05). Accordingly, 41.7% of the VT/VF was terminated spontaneously, and VT/VF inducibility reduced from 91.1% at the baseline to 25% with 10 mg/L sotalol. A higher dose of sotalol (20 mg/L) increased the Smax, despite continuous prolongation of the VERP and APD90, resulting in the increase in the VT/VF inducibility (36.4%). Conclusion:Sotalol produces its anti-fibrillatory effect by APD prolongation in parallel with a flattening of the Smax at therapeutic doses. However, a higher concentration of sotalol increased the Smax and VF inducibility in isolated swine ventricular tissue. (Korean Circulation J 2005;35:282-289)
No takes yet. Share an insight, caveat, or question.
Pak et al. (2005) studied Ventricular fibrillation (n=7). d,l-sotalol vs. Baseline (no sotalol) was evaluated on Maximal slope (Smax) of the action potential duration restitution curve by S1-S2 pacing (p=<0.01). Sotalol at 10 mg/L produced anti-fibrillatory effects by prolonging action potential duration and flattening the maximal slope of restitution, reducing VT/VF inducibility from 91.1% to 25%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: